A method for direct measurement of gradients of patient compliance with a medication regimen by employing a stable non-radioactive isotope taggant compound as part of, bound to, or applied to an endogenous molecule. An assay to determine patient compliance with medication regimens for HIV pre-exposure prophylaxis employing administering a taggant to a pharmacologically active compound, obtaining and collecting a patient tissue or fluid sample analyzing the collected tissue or fluid sample for the taggant concentration and interpreting data from the taggant concentration analysis as an indicator of gradients of patient compliance.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.

Described herein are trehalose analogues. Also described herein are methods of making the trehalose analogues and uses of the analogues. For example, the disclosed trehalose analogues may be useful in the detection of bacteria.

The disclosure relates to binding assays that can measure the binding of ligands to a specific protein target in a micro-radiobinding assay. In particular, the present disclosure relates micro-radiobinding assays useful for low-abundance proteins, such as recombinant or tissue-derived proteins isolated from healthy or diseased, human donor samples.

The disclosure relates to binding assays that can measure the binding of ligands to a specific protein target in a micro-radiobinding assay. In particular, the present disclosure relates micro-radiobinding assays useful for low-abundance proteins, such as recombinant or tissue-derived proteins isolated from healthy or diseased, human donor samples.

The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

The present invention is a method for detecting a specific disease based on the result of a measurement in which the amount of a peptide serving as a biomarker contained in a biological sample is determined by using an LC-MS. A pretreatment process performed before the measurement using the LC-MS includes the steps of preparing a mixed sample solution by adding a stable isotope reagent and a trifluoroacetic acid to the biological sample, where the stable isotope reagent is prepared beforehand by labeling the peptide with a stable isotope; boiling the mixed sample solution; injecting the mixed sample solution after boiled into a solid-phase extraction column to make the peptide be retained in the solid-phase extraction column; and passing a water-soluble organic solvent through the solid-phase extraction column to elute the peptide retained in the solid-phase extraction column and collect the eluate.

A reliable assay to specifically detect CD155 in tissue sections has widespread use because CD155 is expressed widely among tumor types. Additionally, detected expression of CD 155 in glioblastoma cells is at levels commensurate with susceptibility to PVSRIPO (a poliovirus construct) infection and killing. An anti-CD155 antibody can achieve mono-specific detection of CD155 in immunoblots of tumor homogenates and immunohistochemistry of tumor formalin fixed, paraffin embedded sections. The assay can be used to determine appropriate use of PVSRIPO in oncolytic immunotherapy against cancers.